Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ACADEMIA
ACADEMIA
- NCC Sets Sights on World’s Top Development Hub with New Exploratory Clinical Research Center
August 7, 2013
- Draft of Hypertension Guidelines Recommends CCBs, ARBs, ACE Inhibitors, and Diuretics as First-Line Drugs, Excludes Beta Blockers
August 6, 2013
- The Lancet Has Not Received Notification from Jikei University on Investigation Findings: Spokesperson
August 1, 2013
- Ex-Novartis Employee Manipulated Blood Pressure Data in JIKEI Study: Univ. Probe
July 31, 2013
- Role of Companies in Clinical Research Discussed at JAPhMed Annual Meeting
July 24, 2013
- University’s Seriousness to Unravel Diovan Saga Called into Question
July 17, 2013
- Univ. Fails to Question Ex-Novartis Employee over KYOTO Study, Says Internal Probe “Has Limitations”
July 16, 2013
- “Data Manipulated” in KYOTO Heart Study: Univ. Probe
July 12, 2013
- Arzerra, Japan’s 1st Antibody for CLL, Will Expand Treatment Options: Dr Ogawa of Tokai Univ.
July 11, 2013
- Nearly 30% of RA Patients Show LDA 3 Years After Discontinuing Remicade: Prof. Tanaka of Univ. of Occupational and Environmental Health
July 11, 2013
- Orencia Particularly Suitable for Elderly RA Patients: Prof. Takeuchi of Keio University
July 8, 2013
- “No Data Manipulation” in VART Study of Diovan: Interim Report of Japanese Society of Hypertension
July 4, 2013
- NHO Attains 30% Volume-Based Generic Target in FY2012
June 28, 2013
- JSOG Sets Up Investigative Panel on HPV Vaccines to Examine Safety
June 26, 2013
- Dapagliflozin Significantly Reduces Plasma Glucose in PIII Study in Japan, Findings Reported at ADA
June 25, 2013
- SCJ Statement Calls for Close Consultation with Experts in Planning Japanese Version of NIH
June 25, 2013
- Makers Should Venture into Drug Development Using iPS, CiRA Adviser Asonuma Says
June 25, 2013
- More Treatment Options for FD Patients with Acofide Launch: Prof. Kinoshita of Shimane University
June 11, 2013
- Clinical Pharmacology Network to Go Into Operation with 8 Institutions
June 6, 2013
- Japan College of Rheumatology Issues Guidelines on Xeljanz Use
June 6, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…